Wild type KRAS

Biomarker type: Wild type

Gene context: KRAS

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations	Biomarkers	Cancer types	Therapies
FDA (2)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
FDA (2)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
FDA (2)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab
FDA (2)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
FDA (2)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab
EMA (1)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab
EMA (1)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
EMA (1)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Oxaliplatin
EMA (1)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
EMA (2)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
EMA (1)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
FDA (2)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib